Evaluation of special effects and high efficiency of TZ drug coupled with Pamam dendrimer in fourth and fifth generations against breast cancer cells

Purpose: Breast cancer is the most frequently occurring cancer in women worldwide with more than one million new cases diagnosed each year. Human epidermal growth factor receptor2 (Her2) positive breast cancer represents 25% of breast cancer cases. Targeted therapy with Her2 monoclonal antibody, trastuzumab (TZ), represents the first-line treatment for this type of breast cancer. Conjugation of nanocarriers with antibodies that bind to specific membrane receptors that are overexpressed in cancer cells enables targeted delivery.Method: In the studies of Monika Marcinkowska et al, Which have had the most complete review of the materials, The 1H NMR, 13C NMR, FTIR and RP-HPLC were used to analyse the characteristics of the products and assess their purity. The MTT assay was used In the articels to assess cell viability. In addition to,. Statistical Analysis and cell calture was also examined in the articles reviwed.Results: The results of studies performed on TZ drug coupled with fifth generation Pam dendrimer show that The PAMAM-drug-trastuzumab conjugates in particular showed extremely high toxicity toward the HER-2-positive SKBR-3 cells and very low toxicity towards to HER-2-negative MCF-7 cells. In Addition to, The Trastuzumab-dendrimer-fluorine drug delivery system was found to have a higher efficiency in the treatment of Her-2 overexpressing MCF-7 cells than Trastuzumab alone and The results of studies performed on TZ drug coupled with fourth generation Pam dendrimer show that The G4 PAMAM dendrimer showed successful encapsulation of neratinib and a sustained release profile.Conclusions: The results show that the use of Trastuzumab drug coupled with Pamam dendrimer have a higher efficiency against breast cancer cells than Trastuzumab alone.

Keywords:

PAMAM , Trastuzumab , Drug delivery system , Dendrimer , Breast cancer